

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results

April 19, 2022

SOUTH PLAINFIELD, N.J., April 19, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financial results and provide an update on the company's business and outlook on Tuesday, May 3, at 4:30 p.m. ET.

The call can be accessed by dialing (877) 303-9216 (in the United States) or (973) 935-8152 (outside of the United States) five minutes prior to the start of the call and providing the passcode 9963177. A live, listen-only webcast of the conference call can be accessed on the investor section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days following the call.

About PTC Therapeutics, Inc.

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Instagram, Facebook, Twitter, and LinkedIn.

For More Information:

Investors:

Kylie O'Keefe +1 (908) 300-0691 kokeefe@ptcbio.com

Media:

Jeanine Clemente +1 (908) 912-9406 jclemente@ptcbio.com

View original content: https://www.prnewswire.com/news-releases/ptc-therapeutics-to-host-conference-call-to-discuss-first-quarter-2022-financial-results-301525901.html

SOURCE PTC Therapeutics, Inc.